scorecardresearch
Wednesday, April 24, 2024
Support Our Journalism
HomeHealthDisheartening to see some states complaining about Covaxin supply intentions — Bharat...

Disheartening to see some states complaining about Covaxin supply intentions — Bharat Biotech

In a tweet Wednesday, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on 10 May.

Follow Us :
Text Size:

New Delhi: It is quite disheartening to listen to some states complaining about Bharat Biotech’s intentions regarding supply of COVID vaccine Covaxin, a top company official said on Wednesday.

In a tweet, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on May 10.

“18 states have been covered though in smaller shipments. Quite disheartening to the teams to hear some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24×7 for U,” she said in a tweet.

The Hyderabad-based firm is supplying Covaxin to 18 states, including Andhra Pradesh, Haryana, Odisha, Assam, Jammu & Kashmir, Tamil Nadu, Bihar, Jharkhand and Delhi. Other states are Chhattisgarh, Karnataka, Telangana, Tripura, Madhya Pradesh, Uttar Pradesh, Gujarat, Maharashtra and West Bengal.

Earlier in the day, Delhi Deputy Chief Minister Manish Sisodia said Bharat Biotech has informed the state government that it cannot provide “additional” Covaxin doses to the national capital.

The stock of Covaxin in Delhi has finished and as a result around 100 vaccination centres set up in 17 schools have been closed, he said.

“The Covaxin manufacturer has in a letter said that it cannot provide Delhi government vaccines due to unavailability, under instruction of concerned government official. It means that the central government is controlling supply of the vaccine,” Sisodia said.

He also said the Centre should stop export of vaccines and share the vaccine formulae of the two manufacturers in the country with other companies for mass scale production.


Also read: Modi govt expert panel recommends Covaxin for phase 2/3 clinical trials on 2-18-yr-olds


 

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular